BR112023027371A2 - Método para controlar administração de substância ativa ao trato digestivo - Google Patents

Método para controlar administração de substância ativa ao trato digestivo

Info

Publication number
BR112023027371A2
BR112023027371A2 BR112023027371A BR112023027371A BR112023027371A2 BR 112023027371 A2 BR112023027371 A2 BR 112023027371A2 BR 112023027371 A BR112023027371 A BR 112023027371A BR 112023027371 A BR112023027371 A BR 112023027371A BR 112023027371 A2 BR112023027371 A2 BR 112023027371A2
Authority
BR
Brazil
Prior art keywords
active substance
digestive tract
control administration
administration
nutraceuticals
Prior art date
Application number
BR112023027371A
Other languages
English (en)
Portuguese (pt)
Inventor
Aouatef Bellamine
Shane Durkee
Tyler White
Original Assignee
Lonza Greenwood Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Greenwood Llc filed Critical Lonza Greenwood Llc
Publication of BR112023027371A2 publication Critical patent/BR112023027371A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112023027371A 2021-06-24 2022-06-23 Método para controlar administração de substância ativa ao trato digestivo BR112023027371A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163214438P 2021-06-24 2021-06-24
PCT/US2022/034683 WO2022271922A1 (en) 2021-06-24 2022-06-23 Method to control administration of active substance to the digestive tract

Publications (1)

Publication Number Publication Date
BR112023027371A2 true BR112023027371A2 (pt) 2024-03-12

Family

ID=84544830

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023027371A BR112023027371A2 (pt) 2021-06-24 2022-06-23 Método para controlar administração de substância ativa ao trato digestivo

Country Status (8)

Country Link
US (1) US20240285699A1 (cg-RX-API-DMAC7.html)
EP (1) EP4340819A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526149A (cg-RX-API-DMAC7.html)
CN (1) CN117479929A (cg-RX-API-DMAC7.html)
AU (1) AU2022299196A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023027371A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223905A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022271922A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270523B (zh) * 2023-05-15 2023-08-08 四川厌氧生物科技有限责任公司 一种耐酸的口服双层胶囊及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667167C (en) * 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
BR112012006651B1 (pt) * 2009-09-24 2021-11-03 Capsugel Belgium Nv Cápsula farmacêutica dura resistente a ácido e composição aquosa compreendendo goma de gelano e hpmc
DE102010022174A1 (de) * 2010-05-12 2011-11-17 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Darreichungsformen für Cineol
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP3028694B1 (en) * 2014-12-02 2017-07-12 Capsugel Belgium NV Dosage form articles for delayed release
EP3882259B1 (en) * 2015-05-13 2026-01-28 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP4480495A3 (en) * 2017-07-10 2025-06-18 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
US20190388344A1 (en) * 2018-06-22 2019-12-26 Probiotech Llc Method to Improve The Health Of The Microbiome In A Human Gastrointestinal System and Multi-Chamber Probiotic Delivery Products Therefor
US20200038215A1 (en) * 2018-08-01 2020-02-06 Ethicon, Inc. Transient implantable device to control absorption of nutrients
US12144834B2 (en) * 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
CA3117956A1 (en) * 2018-10-30 2020-05-07 Vitabolus Inc. Oral delivery of therapeutic mammalian cells
MX2022004515A (es) * 2019-10-16 2022-07-12 Capsugel Belgium Nv Metodo y composicion para aumentar la sintesis de proteinas musculares.

Also Published As

Publication number Publication date
AU2022299196A1 (en) 2023-12-21
CA3223905A1 (en) 2022-12-29
JP2024526149A (ja) 2024-07-17
CN117479929A (zh) 2024-01-30
EP4340819A4 (en) 2025-04-02
WO2022271922A1 (en) 2022-12-29
EP4340819A1 (en) 2024-03-27
US20240285699A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
Gerunova et al. Butyric acid and prospects for creation of new medicines based on its derivatives: a literature review
Gourley et al. Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice
JP4195728B2 (ja) プロアントシアニジンポリマー止瀉組成物の腸溶製剤
Kallappa et al. Use of high flow nasal cannula oxygen (HFNCO) in infants with bronchiolitis on a paediatric ward: a 3-year experience
NO20053068L (no) Kontrollert avgivelse av en aktiv substans inn i et hoyt fett miljo.
US11110209B2 (en) Intraluminal therapy system for gastrointestinal infections
BR112021017993A2 (pt) Preparações de agente terapêutico e métodos para liberação de fármacos em um lúmen do trato intestinal com o uso de um dispositivo ingerível de liberação de fármacos
GB2477590A (en) A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
BR112022001344A2 (pt) Combinações de antibióticos beta-lactâmicos administrados por via oral e derivados de avibactam para tratamento de infecções bacterianas
AU2016250606A1 (en) Compositions and methods for increasing the susceptibility of bacteria to antibiotics
CO6351716A2 (es) Formulación de liberación modificada y métodos de uso
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
Locci et al. Current uses of bromelain in children: a narrative review
Cai et al. Redox regulation of immunometabolism in microglia underpinning diabetic retinopathy
Chen et al. Gut microbiota and its metabolites: the emerging bridge between coronary artery disease and anxiety and depression?
Lei et al. Clinical efficacy and residue depletion of 10% enrofloxacin enteric-coated granules in pigs
WO2015070131A1 (en) Compositions and methods of treatment comprising fosfomycin disodium
Ivanescu et al. Modifying choroidal neovascularization development with a nutritional supplement in mice
Messeha et al. Nrf2 activation as a therapeutic target for flavonoids in aging-related osteoporosis
Hashimoto et al. Docosahexaenoic acid helps to lessen extinction memory in rats
Michel-Flutot et al. AMPK-Nrf2 signaling pathway in phrenic motoneurons following cervical spinal cord injury
JP2014511896A (ja) 上部気道消化器における微生物関連に関連する状態に使用するための医薬品
BR112021000183A8 (pt) Preparação medicinal para uso externo
BRPI0607172A2 (pt) método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos
Glinkowska et al. Therapeutic Potential of Flavonoids—The Use of Apigenin in Medicine